Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-266989
Filing Date
2025-11-05
Accepted
2025-11-05 16:16:42
Documents
71
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20250930.htm   iXBRL 10-Q 2319959
2 EX-31.1 aldx-ex31_1.htm EX-31.1 18225
3 EX-31.2 aldx-ex31_2.htm EX-31.2 18254
4 EX-32.1 aldx-ex32_1.htm EX-32.1 14159
5 GRAPHIC img131814069_0.jpg GRAPHIC 101648
  Complete submission text file 0001193125-25-266989.txt   8156312

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20250930.xsd EX-101.SCH 967718
74 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20250930_htm.xml XML 1265636
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 251454252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)